Document is current
Any future updates will be listed below
-
Authors
Schwarz, Tobias
Almanzar, Giovanni
Völkl, Sebastian
Feuchtenberger, Martin
Leierer, Johannes
Schmidt, Christian
Deininger, Frank
Tony, Hans-Peter
Schmalzing, Marc
Prelog, Martina
-
Funding
Funding for this research was provided by:
Universitätsklinikum Würzburg
- License Information
-
More Information
Article History
Received: 5 March 2025
Accepted: 15 April 2025
First Online: 22 May 2025
Declarations
:
: The study was approved by the ethics committee at the University of Würzburg (protocol number 239/10) and conducted according to the principles of the Declaration of Helsinki. All participants gave their written informed consent before enrolment.
: Not applicable.
: M.F. received grants from AbbVie and Celltrion, received consulting fees, honoraria for presentations and support for attending meetings from AbbVie, Celltrion, Pfizer and UCB, and participated in advisory boards from AbbVie, Celltrion, Pfizer and UCB. M.S. received consulting fees from AbbVie, Amgen, Hexal/Sandoz, Janssen-Cilag and UCB, honoraria for presentations/lectures from AbbVie and Janssen-Cilag and support for attending meetings from UCB. M.P. received grants from Pfizer, consulting fees from AbbVie, Fresenius Kabi, Janssen-Cilag and Pfizer and honoraria for lectures from AbbVie, Janssen-Cilag and Pfizer. All other authors declare that they have no competing interests.
